A randomized double blind non-inferiority phase III study of efficacy, safety and tolerability of actovex versus avonex in patients with relapsing remitting ms

Authors
Category Primary study
Conference3rd International Congress on Neurology and Epidemiology; 2013 Nov 21-23; Abu Dhabi, United Arab Emirates. Neuroepidemiology
Year 2013
This article has no abstract
Epistemonikos ID: ed22c518a840504685881186cee83044a1d1f307
First added on: Mar 31, 2022